Open Access

Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance

  • Authors:
    • Sooyeun Lee
    • Won‑Jun Jang
    • Boyeon Choi
    • Sang Hoon Joo
    • Chul‑Ho Jeong
  • View Affiliations

  • Published online on: March 28, 2017     https://doi.org/10.3892/ol.2017.5940
  • Pages: 3437-3444
  • Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer is one of the most lethal types of cancer, due to difficulty in early detection and the limited efficacy of available treatments. Erlotinib is used to inhibit the epidermal growth factor receptor for the treatment of pancreatic cancer; however, erlotinib resistance is a major issue and the mechanisms underlying the development of erlotinib resistance remain unclear. To better understand the alterations in tumor metabolism by acquired resistance to erlotinib, an erlotinib‑resistant pancreatic cancer cell line (HPAC‑ER) was established, followed by a comparison of the metabolic characteristics between these cells and their erlotinib-sensitive parental cells (HPAC). This comparison was accomplished through mass spectrometry-based targeted metabolic profiling. Five metabolite groups (acylcarnitines, amino acids and biogenic amines, glycerophospholipids, sphingolipids and monosaccharides) were semi‑quantified and compared statistically. These results revealed significant differences between the two groups of cells. A significant increase in the level of short‑chain acylcarnitines and selected lysophosphatidylcholines, and a significant decrease in the level of acyl‑alkyl‑phosphatidylcholines and one sphingolipid, were observed in the HPAC‑ER cells compared with the HPAC cells. The metabolic changes observed in the present study support the theory that there are increased metabolic demands in erlotinib‑resistant cancer, reflecting the changes in acetyl‑CoA‑associated and choline phospholipid metabolism. These findings will aid in elucidating the changes that occur in pancreatic cancer metabolism through the acquired resistance to erlotinib, and in the identification of biomarkers for the early detection of pancreatic cancer.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee S, Jang WJ, Choi B, Joo SH and Jeong CH: Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. Oncol Lett 13: 3437-3444, 2017
APA
Lee, S., Jang, W., Choi, B., Joo, S.H., & Jeong, C. (2017). Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. Oncology Letters, 13, 3437-3444. https://doi.org/10.3892/ol.2017.5940
MLA
Lee, S., Jang, W., Choi, B., Joo, S. H., Jeong, C."Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance". Oncology Letters 13.5 (2017): 3437-3444.
Chicago
Lee, S., Jang, W., Choi, B., Joo, S. H., Jeong, C."Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance". Oncology Letters 13, no. 5 (2017): 3437-3444. https://doi.org/10.3892/ol.2017.5940